Physician profile
Resha Patel
NPI 1134627201
$3,727.35
in general payments reported to CMS, 2019-2025
25 companies · $515 in 2025
The $515 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,065 · 2022: $1,176 · 2023: $369 · 2024: $602 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,486.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,485.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $730.64 | 2022-2025 | Nanoknife |
| Astellas Pharma US INC | $664.14 | 2021-2023 | Myrbetriq |
| Antares Pharma, INC. | $312.42 | 2021-2023 | Nocdurna, Tlando, Xyosted |
| Coloplast Corp | $289.52 | 2021-2023 | Speedicath |
| Novo Nordisk INC | $241.96 | 2024-2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $206.05 | 2021-2023 | |
| Abbvie INC. | $179.00 | 2021-2023 | |
| Amgen INC. | $157.18 | 2025 | Repatha, Otezla |
| Rochester Medical Corporation | $117.01 | 2022 | |
| Urovant Sciences INC | $91.66 | 2022 | |
| Lilly USA, LLC | $89.59 | 2024 | Zepbound, Mounjaro, Jardiance |
| 180 Medical, INC. | $89.43 | 2021-2022 | |
| Janssen Biotech, INC. | $74.54 | 2021-2022 | |
| Convatec INC. | $67.28 | 2021-2023 | |
| Boston Scientific Corporation | $66.94 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $53.12 | 2021-2022 | |
| Clarus Therapeutics INC. | $50.63 | 2021 | |
| Endo Pharmaceuticals INC. | $49.71 | 2021-2023 | Xiaflex, Aveed |
| Tolmar Pharmaceuticals, INC. | $44.17 | 2021 | |
| Sumitomo Pharma America, INC. | $34.40 | 2023 | Gemtesa |
| Olympus America INC. | $31.79 | 2022 | |
| Viiv Healthcare Company | $30.74 | 2025 | Apretude |
| Accord Healthcare, INC. | $21.44 | 2022 | |
| Procept Biorobotics Corporation | $19.98 | 2022 | |
| Myriad Genetic Laboratories, INC. | $14.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Resha Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.